retatrutide first week UK Guide: Key Facts on the New Weight-Loss Drug 1 Month Retatrutide Results: Clinical

But here is the critical distinction

Persistent vomiting or signs of dehydration also warrant prompt review

Further research is warranted, but boosting endogenous GLP-1 production and activity through nutritional interventions shows promising therapeutic potential across various conditions References: Michaeleen Doucleff

Answer: Retatrutide trials focus on adults with obesity or overweight, typically a BMI at or above 27, who also carry a weight-related condition such as type 2 diabetes, pre-diabetes, high blood pressure, or high cholesterol

In March 2025, Roche and Zealand Pharma launched an Up-to-$5.3B obesity collaboration to co-develop and co-commercialize Zealands petrelintide for overweight and obesity indications

But if youve been considering asking your doctor for a prescription, there are some things you should know first